Empowering Developers to Monetize Anywhere: Xsolla Expands Platform Support for Cross-Platform Direct-to-Consumer Commerce
Unified Commerce Tools Now Available for Windows Stores, Epic Games Store, Discord, Pley, and the Web, Unlocking More Revenue Opportunities for Game Developers
Xsolla, a global commerce company helping developers launch, grow, and monetize their games, announces today a major expansion of its platform support capabilities, reinforcing its position as the premier provider of cross-platform monetization solutions for developers. With the latest SDKs for Windows Stores and the Epic Games Store, a new strategic partnership with Pley, and the launch of the Xsolla Discord Bot, developers can now implement secure, streamlined commerce across PC, mobile, web, and community platforms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250812673202/en/
(Graphic: Xsolla)
Key Platform Expansions Now Available to Developers:
- SDK for Windows stores
PC developers can access flexible monetization tools via Xsolla SDK for Windows Stores, offering seamless checkout flows and cross-platform SKU synchronization for multiplatform titles available on Windows across a variety of game stores. Setup is streamlined and includes built-in access to Pay Station and Login, with optional integration into Web Shop and Buy Button. To learn more, please visit: https://xsolla.com/widows-stores
- SDK for Epic Game Store
PC and mobile developers can seamlessly scale by going direct-to-consumer with Xsolla’s SDK for the Epic Games Store, which enables smooth integration, dual billing options for mobile, synchronized inventory, localized native checkout experiences, and built-in support for subscriptions, recurring billing, Buy Button, and Web Shop. To learn more, please visit: https://xsolla.com/epic-games-store.
- Xsolla Discord Bot: Conversational Commerce
Developers can now activate commerce directly inside Discord, turning conversations into conversion opportunities via Web Shop integration. Xsolla Discord Bot enables studios to showcase products, offer promotions and goal-based incentives, and sell digital goods through real-time messages and server channels. To learn more, please visit: https://xsolla.com/discord-bot.
- Pley Partnership: Seamlessly Bring Your Unity Game to the Web
Mobile developers can now launch web-based versions of their games with minimal effort through Xsolla’s partnership with Pley, which combines Pley’s cloud-based toolchain for Unity games with Xsolla’s global payment infrastructure to unlock new revenue streams, diversify their strategies, and connect more directly with players.
“The future of game commerce is direct, cross-platform, and player-centric. Our goal is to give developers the freedom to monetize on their terms across any platform, any channel, anywhere in the world,” said Chris Hewish, President at Xsolla. “This platform expansion delivers on that promise with streamlined commerce tools that eliminate complexity and unlock scalable growth.”
This initiative marks another milestone in Xsolla’s ongoing mission to democratize game commerce. As platform rules tighten and player journeys become more complex, Xsolla continues to meet developers where they are, enabling them to grow their games their way.
For a complete list of enhancements and developer tools, visit: https://xsolla.com/release-notes/august-2025#platform-solutions
About Xsolla
Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250812673202/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom